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The growth factor progranulin has emerged in recent years as a critical regulator of
transformation in several cancer models, including breast cancer, glioblastomas, leukemias, and hepatocellular carcinomas. Several laboratories, including ours, have also
demonstrated an important role of progranulin in several genitourinary cancers, including
ovarian, endometrial, cervical, prostate, and bladder tumors, where progranulin acts as
an autocrine growth factor thereby modulating motility and invasion of transformed cells.
In this review, we will focus on the mechanisms of action and regulation of progranulin
signaling in genitourinary cancers with a special emphasis on prostate and bladder
tumors.
Keywords: progranulin, bladder and prostate cancer, motility, anchorage-independent growth, tumor formation
in vivo

INTRODUCTION
Progranulin, also known as proepithelin, granulin–epithelin precursor, acrogranin, and PC cellderived growth factor, is a secreted glycoprotein with dual cellular roles, both as a growth factor
regulating cell proliferation and wound repair and as a component of the transforming machinery
in several cancer systems (1–3). Progranulin regulates inflammation and neurodegeneration (4) and
has been linked to the development of frontotemporal dementia (FTD) (4).
Progranulin contains seven and a half granulin-like domains, which are ~6 kDa peptides called
granulins (granulin A to G and paragranulin). These domains contain highly conserved tandem
repeats of 12-cysteine residues, with the exception of granulin G, which has only 10 cysteine residues.
The progranulin precursor is a 68.5-kDa protein of 593 amino acids, which migrates at ~88 kDa on
Western immunoblot due to glycosylation (5).
Historically, granulins were first discovered as a novel class of leukocyte peptides with cytokinelike activities (6, 7). The progranulin precursor protein was later purified from PC cell-derived
conditioned medium by Zhou et al. (8), who demonstrated the function of progranulin as mitogen and an autocrine growth factor for cancer cell lines. This precursor protein was identical to
a growth-promoting factor later purified by Dr. Baserga’s group from the conditioned media of
BRL-3A rat liver cells (8), which was able to induce cell proliferation of R− cells, derived from mice
with a targeted deletion of the insulin-like growth factor receptor (IGF-IR) gene (9). Significantly,
progranulin was the only known growth factor able to bypass the requirement for the IGF-IR, thus

Frontiers in Endocrinology | www.frontiersin.org

1

July 2016 | Volume 7 | Article 100

Tanimoto et al.

Progranulin Action and Regulation

United States (12). Human papillomavirus (HPV) infection is the
prevalent cause of cervical cancer as in fact over 99% of cervical
cancers are positive for HPV (27). However, only a small fraction
of women infected by HPV develops cervical cancer suggesting
that other factors contribute to its progression.
Progranulin overexpression or recombinant progranulin
protein stimulated transformation of HPV16-immortalized
cervical mucosa epithelial H8 cells in vitro and in vivo (28, 29).
On the contrary, inhibition of progranulin expression by siRNA
approaches inhibited growth (28, 30).
Endometrial cancer is the most common genital cancer
among women in United States, with an estimated 60,050 new
cases in 2016 (12). The risk factors are related to an increase in
circulating estrogens secondary to obesity, chronic anovulation
and nulliparity estrogen replacement therapy, and tamoxifen
use. Endometrial cancer tissues showed upregulated progranulin expression in association with estrogen receptor (31), and
progranulin expression level was increased after estradiol and/
or tamoxifen treatment in vitro (31). Similar to cervical cancer,
inhibition of progranulin with shRNAs resulted in decreased
endometrial cancer cell proliferation (31).
These results suggest that in endometrial cancer progranulin
may work in estradiol-dependent fashion and mediate, at least
in part, estrogen receptor-dependent biological responses. This
is reminiscent of progranulin action in breast cancer, where progranulin (PCDGF/granulin precursor) expression is stimulated
by estradiol (32) and progranulin regulates estrogen-dependent
mitogenesis (33).

promoting growth of R− cells (10). As demonstrated by He et al.,
progranulin o
 verexpression in adrenal carcinoma and renal epithelial cells resulted in enhanced progranulin secretion, increased
mitogenesis, and tumorigenesis (11). Progranulin has been
shown to enhance proliferation and promote tumor growth in
several cancer cell lines, such as breast, gastrointestinal, hepatic,
lung, and genitourinary cancers. In this manuscript, we review
progranulin’s dual roles as a novel transforming growth factor and
a clinical diagnostic and prognostic biomarker in genitourinary
cancers.

PROGRANULIN IN OVARIAN CANCER
Ovarian cancer (OC) is the deadliest gynecological cancer and is
the fourth leading cause of cancer-related deaths in women (12).
While current treatment with surgery and chemotherapy can
manage early stage disease, patients with late stage disease often
recur and develop distant metastases. From the initial diagnosis,
the median 10-year survival is only about 40% (13). Thus, it is
very important to identify novel predictors of ovarian tumor
progression.
Progranulin action in OC has been well characterized. Jones
et al. (14) compared progranulin expression between low malignant potential and invasive ovarian tumors and demonstrated
that progranulin expression was upregulated in invasive OC
compared to low-grade tumors (15), suggesting that progranulin
expression may be predictive of tumor progression. Progranulin
mRNA and protein expression levels were significantly higher
in tissue samples obtained from OC when compared to benign
and normal ovarian tissues (15–17). Furthermore, progranulin
expression level was correlated with higher stage and worse
prognosis in OC patients (16–20).
Furthermore, numerous in vitro and in vivo studies have
demonstrated the role of progranulin in promoting proliferation,
resistance to apoptosis, and motility of OC cells, where progranulin activates mitogen-activated protein kinase (MAPK) and
MMP-2 signaling (14, 17, 20–22).
Another potential serum marker for OC is serum leukocyte
protease inhibitor (SLPI), a serine protease inhibitor protein,
whose levels are elevated in serum derived from patients with
OC (23). Significantly, SLPI protects progranulin from serine
proteases and cleavage into mature granulins (24). Devoogdt
et al. demonstrated that SLPI overexpression protected progranulin from elastase-mediated degradation and increased OC
growth and survival, both in vitro and in vivo (25, 26). Han et al.
reported that among progranulin, SLPI, and the FDA approved
serum biomarkers HE4 and CA125, progranulin was the only
biomarker independently associated with poor prognosis in OC
patients in remission after initial surgical cytoreduction and
chemotherapy (18).

PROGRANULIN ACTION IN
BLADDER CANCER
Bladder cancer is the fourth most common cancer in men in
developed countries, with high recurrence rates of around 60%
after treatment (12, 34, 35). The vast majority of early stages bladder tumors present as low-grade non-invasive papillary tumors
(Ta stage). The remaining comprises tumors that have penetrated
the basement membrane but not invaded the muscle layer of
the bladder wall (T1 stage) and muscle-invasive tumors (T2–T4
stages) (36). The prognosis for low-grade tumors is generally
good but about 15% of low-grade tumors progress to invasive
disease. For invasive tumors, patient survival is ~50% at 5 years
(37). Invasive tumors are frequently associated with metastases,
which have a 5-year survival rate of 6% (37). However, despite
the significant clinical impact of bladder cancer, there is still an
urgent need to discover drivers of disease progression and novel
therapeutic targets.
In recent years, our laboratories have established that progranulin plays a critical role in bladder cancer by regulating
bladder cancer cell motility, invasion, anchorage-independent
growth, and tumor formation in vivo (38–41).
We initially demonstrated that recombinant human progranulin did promote migration, wound closure, and invasion
of urothelial cancer cells (42). Progranulin-mediated biological
responses required the activation of the MAPK pathway and
paxillin, which upon progranulin stimulation formed a complex

PROGRANULIN IN CERVICAL AND
ENDOMETRIAL CANCER
Cervical cancer is the third most common cancer among women
worldwide and the third most common genitourinary cancer in
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with focal adhesion kinase (FAK) and active extracellular signalregulated kinase (ERK) at the leading edge of migrating urothelial
cancer cells (42). These results suggested that progranulin-induced
cell motility might be regulated by the ability of progranulin to
modulate focal adhesion dynamics of motile cancer cells.
We later discovered that urothelial cancer cells abundantly
secrete progranulin (39). Significantly, stable depletion by
shRNA approaches of endogenous progranulin expressed in T24
urothelial carcinoma-derived cell inhibited both the Akt and
MAPK pathways, reduced the ability of T24 cells to proliferate in
the absence of serum and inhibited motility, wound healing and
invasion in vitro (39). Collectively, these results demonstrated
that progranulin acts as a tumorigenic autocrine growth factor
for bladder cancer cells and may work as a biomarker for bladder
neoplasms.
In order to gain further insights into the molecular mechanisms of progranulin action in bladder cancer, we searched for
novel progranulin-interacting proteins using pull-down assays
with recombinant progranulin and proteomic analysis. We demonstrated that drebrin (developmentally regulated brain protein),
an F-actin binding protein (43, 44), interacted with progranulin
in urothelial cancer cells (40), modulated progranulin-induced
MAPK and Akt signaling, and promoted progranulin-dependent
motility and invasion by regulating F-actin remodeling (40).
In addition, drebrin was essential for anchorage-independent
growth in vitro and tumor formation in vivo, and its expression
was upregulated in bladder cancer tissues compared to normal tissue controls (40). Our data demonstrated an essential functional

role for drebrin in the regulation of progranulin actions suggesting that drebrin may constitute a novel target for therapeutic
intervention in bladder tumors. In addition, drebrin may work as
novel biomarker for bladder cancer progression (Figure 1).
Given the critical role of progranulin in regulating motility
and invasion of urothelial cancer cells (39, 40, 42), we then
determined whether targeting progranulin could have therapeutic efficacy in bladder cancer. Thus, we very recently generated
progranulin-depleted tumorigenic urothelial cancer cells and
demonstrated that progranulin targeting markedly reduced
in vivo tumor growth of UMUC-3 cells in both orthotopic and
subcutaneous xenograft tumor models (41). The immunostaining
analysis of orthotopic tumors derived from progranulin-depleted
UMUC-3 cells tumors had significantly lower expression level
of Ki67, a cellular marker of proliferation, compared to tumor
tissues derived from control-transfected cells (41). Moreover, the
F-actin network of orthotopic tumors derived from progranulindepleted cells was intact and well assembled compared to controls (41), supporting our previous in vitro results (40) and the
hypothesis that progranulin might regulate invasion and motility
of urothelial cancer cells by modulating F-actin remodeling.
Significantly, tumor tissues derived from UMUC-3/Control
orthotopic xenografts showed reduced expression of the epithelial marker E-cadherin and increased levels of the mesenchymal
protein vimentin compared to progranulin-depleted orthotopic
xenografts. These results would suggest that the role of progranulin in bladder cancer tumor formation might be associated with
an epithelial-to-mesenchymal transition (EMT) (45), which is

Figure 1 | Progranulin signaling in bladder cancer. The schematic draw summarizes the current knowledge of progranulin signaling pathways leading to
motility and invasion of bladder cancer cells. Progranulin interaction with the unidentified progranulin membrane receptor mediates progranulin internalization and
interaction with the F-actin protein drebrin, thus regulating MAPK and Akt pathways and cytoskeletal remodeling (40). Additionally, progranulin signaling activates
paxillin, which may contribute with MAPK in regulating the dynamic of focal adhesions.
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severely affected by progranulin ablation in urothelial cancer
cells. These results are consistent with data showing that in OC
progranulin induces motility and invasion through EMT and the
activation of cancer-associated fibroblasts (20).
The standard of care for invasive and metastatic bladder cancer
is based on platinum-containing anti-cancer drugs, such as cisplatin (46). Progranulin depletion significantly enhanced cisplatindependent cell death as compared to control bladder cancer cells
(41), suggesting that progranulin targeting in combination with
cisplatin could enhance the therapeutic efficacy of cisplatin-based
therapy in invasive bladder tumors.
Because progranulin might be secreted in the urine either
through active secretion or after cell death, initially we assessed
progranulin levels in concentrated urines of healthy subjects and
demonstrated that progranulin can be detected in urine using
immunoblots (39). Furthermore, progranulin levels in urine were
quantified by enzyme-linked immunosorbent assay (ELISA) (39).
Significantly, Soukup et al. (47) tested by ELISA assay the urinary
concentrations of 27 biomarkers, including progranulin, for the
detection of primary and recurrent urothelial bladder cancers.
Importantly, the urinary concentration of progranulin was
significantly higher in patients with bladder cancer compared to
healthy subjects (47). However, progranulin levels did not show
significant difference between patients with cancer recurrence
and patient without recurrence (47). Taking into account the
sample size limitation of this study, additional analyses on larger
cohorts are necessary to establish whether progranulin may work
as a urine biomarker for bladder cancer.
We recently analyze by immunohistochemistry progranulin
expression levels in a human bladder tumor microarray containing 69 validated cases, including various types and stages of
bladder cancers. Progranulin was barely detectable in normal
bladder. In contrast, all malignant bladder tumors exhibited a
significantly increased progranulin expression with the only
exception of mucinous carcinoma where progranulin levels were
comparable to normal tissues (41). Progranulin upregulation
was not statistically different between low-grade and high-grade
invasive urothelial carcinoma tissues (41). Progranulin was
also upregulated in metastatic bladder tissues suggesting that
progranulin expression levels might be associated with bladder
cancer metastases. We additionally tested progranulin expression
levels in archived paraffin-embedded tissues derived from noninvasive carcinoma in situ (Tis), non-invasive low-grade papillary
carcinomas (Ta), non-invasive high-grade papillary carcinomas
(Ta) using as control normal, and invasive high-grade carcinoma.
Progranulin expression levels were significantly upregulated in
non-invasive low-grade papillary carcinomas (Ta) compared to
benign tissues and enhanced in both non-invasive high-grade
papillary carcinomas (Ta) and high-grade carcinoma tissues
compared to benign tissues, while in non-invasive carcinoma
in situ (Tis) progranulin expression was at levels similar to benign
tissues (41). These results were somewhat surprising considering
the importance of progranulin in regulating motility and invasion
and suggest that progranulin expression is predictive of bladder
tumor formation but do not discriminate between superficial and
invasive urothelial carcinomas. On the contrary, drebrin expression correlated with bladder tumor progression (40) indicating
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that expression levels of downstream progranulin effectors may
be more predictive of bladder tumor progression than progranulin itself.

PROGRANULIN ACTION
IN PROSTATE CANCER
Prostate cancer is the most common cancer in men and is also
the second leading cause of cancer-related deaths in men (12). In
the developed world, most prostate cancers are diagnosed at an
early stage where the cancer is confined to the prostate or local
organs, with minimal risk of disease progression after treatment.
However, a significant proportion of men with clinically localized
prostate cancer treated with radical prostatectomy will develop
biochemical recurrence, subsequent local recurrence, and distant
metastases (48–50). Furthermore, the mechanisms promoting
progression to the castration-resistant stage of prostate cancer
(CRPC) are still very poorly characterized.
We previously established that progranulin is not expressed
in androgen-responsive LNCaP prostate cancer cells but instead
acts as an autocrine growth factor for DU145 cells and promotes
castration-resistant prostate cancer cell motility, invasion, and
anchorage-independent growth (38). This study supported the
hypothesis that progranulin was not important for prostate cancer initiation but might play an important role in prostate cancer
progression and CRPC.
Sortilin, a single-pass type I transmembrane protein of
the Vps10 family, binds progranulin in neurons and mediates
progranulin targeting for lysosomal degradation (51). However,
the role of sortilin in cancer is still very poorly characterized. In
addition, whether sortilin is expressed in prostate cancer cells and
plays any role in regulating progranulin action in prostate cancer
has not previously established. Androgen-responsive LNCaP cells
express very low levels of endogenous progranulin, do not respond
to exogenous recombinant progranulin and do not express
sortilin (52), suggesting that the progranulin/sortilin functional
interaction may have a prevalent role in castration-resistant prostate cancer. Accordingly, in castration-resistant DU145 and PC3
cells, we detected very low levels of sortilin, which was associated
with high levels of progranulin production and enhanced motility and invasion (52). Restoring sortilin expression in PC3 and
DU145 cells decreased progranulin levels and inhibited motility,
invasion, and anchorage-independent growth (52). These results
were recapitulated by depleting endogenous progranulin in PC3
and DU145 cells. On the contrary, targeting endogenous sortilin
by shRNA approaches enhanced progranulin levels and sustained
motility, invasion, and anchorage-independent growth (52).
Similar to OC, Zheng et al. (53) reported that SLPI is overexpressed in CRPC patients and supports CRPC cell growth and
invasion by functionally interacting with progranulin (53). SLPI
overexpression in prostate cancer cells provides a proliferative
advantage after castration by its anti-protease activity toward
elastase and protecting progranulin from elastase-dependent
degradation (53).
These results suggest that the functional interaction between
sortilin, SLPI, and progranulin levels may be critical for prostate
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Figure 2 | Sortilin-dependent regulation of progranulin action in prostate cancer. Sortilin promotes progranulin uptake through clathrin-dependent
endocytosis and targets progranulin for degradation in the lysosomes. Sortilin loss is associated with enhanced progranulin levels and action in castration-resistant
prostate cancer cells.

cancer, and sortilin/SLPI loss may contribute to progranulindependent action in prostate cancer progression (Figure 2).
The role of progranulin as a prostate cancer biomarker has not
been clearly defined, and the data are also partially discordant. We
investigated progranulin expression levels in available prostate
cancer microarray studies using the ONCOMINE database (42).
We found that progranulin mRNA expression was significantly
increased in six primary prostate cancer data sets compared to
controls (54–59). Additionally, primary tumors that have been
treated with hormone therapy showed decreased progranulin
mRNA levels (57). However, three studies showed contradictory
results demonstrating that metastatic cancers had decreased progranulin expression levels compared to non-metastatic prostate
cancers (54, 55, 60).
We evaluated by immunohistochemical analysis progranulin
expression levels in normal versus prostate cancer sections and
demonstrated that progranulin was expressed at low levels, in
normal prostate but was instead upregulated in tumor glands
(42), confirming the data by Pan et al. (61), who assessed progranulin (GP88) in normal prostate, prostatic intraepithelial
neoplasia, and prostatic adenocarcinoma tissues. However, due
to the limited sample size of both studies, additional analyses are
indeed required to clearly define progranulin as a biomarker for
prostate cancer progression.

models. However, the mechanisms of progranulin action are
still poorly characterized. Experiments are currently under way
to identify novel regulators of progranulin signaling, which may
constitute novel targets for therapy in tumors where progranulin
plays a role.
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CONCLUSION
A vast body of evidence has emerged in support of the critical role
of progranulin in promoting transformation of several cancer
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